Search Results
Oct 30, 2025, 02:20 ET JETOUR T1 i-DM Hadir di Filipina, Pimpin Tren "Smart Hybrid"
JETOUR resmi meluncurkan T1 i-DM di Filipina. Sebagai varian hybrid dari seri T1, T1 i-DM mewarisi filosofi desain JETOUR "New Rugged" yang memadukan ketangguhan dan gaya modern sekaligus memimpin tren baru di segmen SUV. Dengan konsep "PHEV Urban SUV", T1 i-DM memenuhi beragam kebutuhan
More news about: Jetour
Oct 29, 2025, 09:30 ET ZEPIC Becomes the First AI Platform to Turn Every Instagram Interaction Into a Revenue Win
capture the real intent behind every comment, DM, or reaction, nor can they re-engage those users across touchpoints. ZEPIC changes that." The real power begins once these interactions flow back into ZEPIC's Marketing OS. Every DM, comment, or converted follower becomes a valuable
More news about: ZEPIC, Inc.
Oct 27, 2025, 11:15 ET Neurotronic Announces Presentation of First Clinical Outcomes of Multi‑Organ Denervation for Type 2 Diabetes and Hypertension
clinical outcomes of Neuviant™ Multi‑organ Denervation (MDN – hepatic and renal denervation) in patients with both type 2 diabetes mellitus (T2DM) and hypertension (HTN), two of the most prevalent and difficult‑to‑treat, chronic diseases worldwide, were presented at Transcatheter Cardiovascular
More news about: Neurotronic
Oct 27, 2025, 08:31 ET MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting
fibrosis, and improved glucose control. Furthermore, in Phase 1a, 1b and 2a trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.
More news about: MetaVia Inc.
Oct 27, 2025, 08:30 ET Employees Retirement System of Texas Adopts New Bloomberg Equity Index as Policy Benchmark
bespoke customization capabilities for benchmarking, asset allocation, and product creation. Core benchmarks include the World (WORLD), Developed Markets (DM) and Emerging Markets (EM) Large and Mid Cap Indices, as well as the Bloomberg 500 (B500) Index. For more information on Bloomberg's
More news about: Bloomberg
Oct 26, 2025, 13:07 ET Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
for the treatment of Duchenne muscular dystrophy (DMD), delpacibart etedesiran (del-desiran) for the treatment of myotonic dystrophy type 1 (DM1) and delpacibart braxlosiran (del-brax) for the treatment of facioscapulohumeral muscular dystrophy (FSHD). SpinCo will
More news about: Avidity Biosciences, Inc.
Oct 24, 2025, 08:00 ET Neurotronic Announces First Clinical Outcomes of Multi‑Organ Denervation for Type 2 Diabetes and Hypertension
clinical outcomes of Neuviant™ Multi‑organ Denervation (MDN – hepatic and renal denervation) in patients with both type 2 diabetes mellitus (T2DM) and hypertension (HTN), two of the most prevalent and difficult‑to‑treat, chronic diseases worldwide. These results represent the first reported outcomes
More news about: Neurotronic
Oct 22, 2025, 15:11 ET Manychat Launches First-Ever Follow to DM Feature, Turning Every New Instagram Follower into a Conversation
community made that crystal clear, and Follow to DM is a massive step towards deeper connections between creators and their audience: a simple, instant way to forge lasting relationships that make social media more social." Follow to DM can be switched on in seconds using the "Say
More news about: Manychat
Oct 22, 2025, 09:40 ET LEPAS otevírá svůj první dům elegantního životního stylu a globálně uvádí na trh elegantní technologii LEPAS
content:https://www.prnewswire.com/news-releases/lepas-otevira-svj-prvni-dm-elegantniho-ivotniho-stylu-a-globaln-uvadi-na-trh-elegantni-technologii-lepas-302591538.html
More news about: Chery Group
Oct 22, 2025, 08:26 ET DirectMail2.0, LLC Launches World's First AI-Powered Direct Mail Marketing Analysis Tool at Printing United Alliance Convention
https://www.linkedin.com/company/directmail2 DM2-Modelling-Architecture-1.docx
More news about: DirectMail2.0, LLC.
Oct 20, 2025, 12:48 ET Long-Term Study of Extended-Release Guaifenesin Shows Symptom Relief in Stable Chronic Bronchitis Patients
12-hour products that work to thin and loosen excess mucus, relieve chest congestion, and control coughing. The Mucinex 12-Hour line, including Mucinex DM for cough and chest congestion and Mucinex SE for chest congestion, provides powerful, long lasting relief day or night. Mucinex
More news about: MUCINEX
Oct 20, 2025, 01:44 ET Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
on-treatment deaths were observed in trastuzumab botidotin, compared with 1.6% in T-DM1, all of which were considered unrelated to treatment. As a conclusion, this second head-to-head trial comparing T-DM1 with other anti-HER2 regimens demonstrated that trastuzumab botidotin statistically
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 20:10 ET 歌禮完成小分子GLP-1R激動劑ASC30治療肥胖症的每月一次皮下儲庫型治療制劑的美國IIa期研究受試者入組
歌禮將於中國標準時間今日（2025年10月20日）上午10:00舉行電話交流會（普通話）。可通過騰訊會議/VooV會議號：216-282-339，或如下的鏈接參與直播： 中國內地[1]：https://meeting.tencent.com/dm/8LbPT9Fs9HoW；或 國際：
More news about: 歌禮製藥有限公司
Oct 19, 2025, 20:10 ET Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
https://meeting.tencent.com/dm/8LbPT9Fs9HoW; orInternational: https://voovmeeting.com/dm/8LbPT9Fs9HoW.
More news about: Ascletis Pharma Inc.
Oct 17, 2025, 05:42 ET Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
multi-center, randomized, open-label, controlled, Phase 3 KL166-III-06 study that evaluates the efficacy and safety profile of trastuzumab botidotin versus T-DM1 in patients with HER2-positive unresectable or metastatic BC who have received prior trastuzumab and taxane-containing regimens. At a pre-specified
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 16, 2025, 09:00 ET Avidity Biosciences to Participate in Upcoming Investor Conference
targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology
More news about: Avidity Biosciences, Inc.
Oct 15, 2025, 09:03 ET Deck Bio and ReTrax Therapeutics Awarded 2025 Bristol Myers Squibb Golden Tickets
pathogenic repeat expansions, delivering a durable, disease-modifying approach for Huntington's disease (HD) first, with expansion to myotonic dystrophy (DM1) and other repeat expansion disorders (REDs). About LabCentral A private,
More news about: LabCentral
Oct 14, 2025, 15:36 ET Welcoming Ren Crypto Fish as our newest General Partner
than any prior financial system. From a cold DM to shaping the future of crypto marketsRen originally found Electric Capital through a cold DM on Twitter in April 2021 asking about developer data. What began as a thoughtful question
More news about: Electric Capital
Oct 13, 2025, 09:00 ET Collective Voice Expands Creator-in-Residence Program to Power Next Generation of Creator Education and Innovation
" : An AI-powered, automated Instagram direct message (DM) feature allowing creators to maintain authentic connections while saving valuable time for content creation and community building. The tool streamlines
More news about: Collective Voice
Oct 13, 2025, 09:00 ET Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology
More news about: Avidity Biosciences, Inc.
Oct 09, 2025, 03:00 ET ARTHEx Biotech to Participate in Upcoming Investor and Industry Events
tissue-specific delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional
More news about: ARTHEx Biotech
Oct 08, 2025, 10:00 ET DM Clinical Research Forms Inaugural Advisory Board to Accelerate Growth and Innovation
8, 2025 /PRNewswire/ -- DM Clinical Research, a leading multi-therapeutic site network, today announced the formation of its inaugural Advisory Board. Comprising respected leaders from clinical research and healthcare, the Board will provide strategic counsel to DM Clinical's Executive Leadership
More news about: DM Clinical Research
Oct 07, 2025, 06:57 ET ID Privacy AI Launches Social Pro, The New Standard For Social Media Conversational AI Agents
social media exchange , underscoring the need for consistent, high-quality engagement. Operating 24/7, Social Pro ensures every DM - whether received at midnight or 8 a.m. - gets an immediate, context-aware reply. By engaging customers in real time, businesses can dramatically
More news about: ID Privacy, Inc.
Oct 06, 2025, 09:00 ET Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology
More news about: Avidity Biosciences, Inc.
Oct 03, 2025, 15:24 ET Little-Known Fact: The All-Electric Armored Lac Hong 900 LX Is Built on the VinFast VF 9 Platform
threats; successfully withstood over 400 laser guided rounds during live ballistic testing; certified to withstand the simultaneous detonation of two DM51 hand grenades beneath critical areas of the floor, a rare and exceptional achievement in EV engineering, especially given the protection of the high-voltage
More news about: Vinfast Auto LLC